CO2020006552A2 - Composiciones farmaceuticas que comprenden safinamida - Google Patents

Composiciones farmaceuticas que comprenden safinamida

Info

Publication number
CO2020006552A2
CO2020006552A2 CONC2020/0006552A CO2020006552A CO2020006552A2 CO 2020006552 A2 CO2020006552 A2 CO 2020006552A2 CO 2020006552 A CO2020006552 A CO 2020006552A CO 2020006552 A2 CO2020006552 A2 CO 2020006552A2
Authority
CO
Colombia
Prior art keywords
safinamide
pharmaceutical compositions
particles
taste
preparing
Prior art date
Application number
CONC2020/0006552A
Other languages
English (en)
Inventor
Alberto Moretto
Lazzari Alessandra De
Fabiana Mazzara
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of CO2020006552A2 publication Critical patent/CO2020006552A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas que comprenden safinamida y, más particularmente, con partículas con sabor enmascarado que comprenden dicho ingrediente activo o sales farmacéuticamente aceptables de las mismas, formas de dosificación oral que incluyen dichas partículas y un proceso para prepararlas.
CONC2020/0006552A 2017-11-02 2020-05-28 Composiciones farmaceuticas que comprenden safinamida CO2020006552A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201700124545 2017-11-02
PCT/EP2018/079635 WO2019086408A1 (en) 2017-11-02 2018-10-30 Pharmaceutical compositions comprising safinamide

Publications (1)

Publication Number Publication Date
CO2020006552A2 true CO2020006552A2 (es) 2020-08-21

Family

ID=61527030

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006552A CO2020006552A2 (es) 2017-11-02 2020-05-28 Composiciones farmaceuticas que comprenden safinamida

Country Status (13)

Country Link
US (1) US11103457B2 (es)
EP (1) EP3703665A1 (es)
JP (1) JP2021508316A (es)
CN (1) CN111432806A (es)
AU (1) AU2018357886B2 (es)
BR (1) BR112020008653A2 (es)
CA (1) CA3080975A1 (es)
CO (1) CO2020006552A2 (es)
EA (1) EA202091127A1 (es)
IL (1) IL274144A (es)
MX (1) MX2020004403A (es)
WO (1) WO2019086408A1 (es)
ZA (1) ZA202003079B (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096392A1 (en) * 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2011098456A1 (en) 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
JP5680898B2 (ja) * 2010-08-10 2015-03-04 京都薬品工業株式会社 苦味を抑制した速崩壊錠
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
PT2594266E (pt) 2011-11-17 2014-11-03 Zambon Spa Composições farmacêuticas sólidas que contêm sais de ibuprofeno
US9474713B2 (en) * 2013-02-14 2016-10-25 Sanofi Chewable composition for oral administration and process for preparing thereof
ES2761407T3 (es) * 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación rápidamente dispersable de topiramato
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
CA2955972A1 (en) * 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
CN104546747A (zh) 2014-11-20 2015-04-29 美吉斯制药（厦门）有限公司 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法
ITUA20163981A1 (it) * 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
CN106667940A (zh) * 2017-02-22 2017-05-17 佛山市弘泰药物研发有限公司 一种沙芬酰胺分散片及其制备方法
CN106983730A (zh) * 2017-02-22 2017-07-28 佛山市弘泰药物研发有限公司 一种沙芬酰胺胃溶型微丸片及其制备方法

Also Published As

Publication number Publication date
EP3703665A1 (en) 2020-09-09
EA202091127A1 (ru) 2020-09-22
CN111432806A (zh) 2020-07-17
WO2019086408A1 (en) 2019-05-09
IL274144A (en) 2020-06-30
AU2018357886B2 (en) 2024-04-18
JP2021508316A (ja) 2021-03-04
MX2020004403A (es) 2020-08-06
BR112020008653A2 (pt) 2020-10-27
ZA202003079B (en) 2023-02-22
AU2018357886A1 (en) 2020-05-07
US11103457B2 (en) 2021-08-31
CA3080975A1 (en) 2019-05-09
US20200315969A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
ECSP17084331A (es) Formulaciones farmacéuticas
BR112015018087A8 (pt) composto, composição farmacêutica e uso
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
BR112016029750A2 (pt) dosagem intermitente de inibidor mdm2
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
BR112017028140A2 (pt) formulações farmacêuticas
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
EA201890532A1 (ru) Новые аннелированные бензамиды
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
PH12016502527B1 (en) Stabilized desmopressin
UY36958A (es) Compuestos para administración intracelular
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας